| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.81 M USD | -9.59 M USD | -17.94 M USD | -15.15 M USD | -17.88 M USD | -16.57 M USD | -16.37 M USD | -14.56 M USD | -11.92 M USD | -16.29 M USD | -22.99 M USD | -22.64 M USD |
| Depreciation & Amortization | 200000 USD | 310000 USD | 362000 USD | 372000 USD | 488000 USD | 376000 USD | 239000 USD | 232000 USD | 769000 USD | 697000 USD | 325000 USD | 277000 USD |
| Stock-Based Compensation | 127000 USD | 478000 USD | 670000 USD | 862000 USD | 1.31 M USD | 1.35 M USD | 1.51 M USD | 2.09 M USD | 499000 USD | 949000 USD | 2.15 M USD | 2.68 M USD |
| Capital Expenditures | 90000 USD | 60000 USD | 149000 USD | 122000 USD | 219000 USD | 298000 USD | 490000 USD | 198000 USD | 259000 USD | 117000 USD | 199000 USD | 351000 USD |
| Cash Flow from Investing | -90000 USD | -60000 USD | 330000 USD | 14.73 M USD | -219000 USD | -267000 USD | -490000 USD | -198000 USD | -259000 USD | -4.12 M USD | -199000 USD | -351000 USD |
| Cash Flow from Financing | 6.94 M USD | 10.96 M USD | 3.68 M USD | 9.42 M USD | 27.87 M USD | 30.02 M USD | 12.66 M USD | 4.65 M USD | 26.45 M USD | -1.36 M USD | 15.05 M USD | 89000 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -10.90 M USD | -9.65 M USD | -18.09 M USD | -15.27 M USD | -18.10 M USD | -16.87 M USD | -16.86 M USD | -14.76 M USD | -12.18 M USD | -16.41 M USD | -23.19 M USD | -23.00 M USD |
Nuwellis Inc. is a medical technology company that develops, manufactures, and commercializes medical devices for ultrafiltration therapy to manage fluid overload in patients with cardiorenal conditions. Its primary products include the Aquadex FlexFlow and Aquadex SmartFlow systems, which provide clinicians with precise, safe methods to remove excess salt and water from patients whose conditions are unresponsive to diuretics, particularly those suffering from heart failure, critical care challenges, and pediatric cases. The Aquadex systems consist of a console with electromechanical pumps and display screen, disposable blood circuit sets with tubing, filters, sensors, and connectors, and disposable catheters. These devices support both temporary and extended use in adult and pediatric patients weighing 20 kilograms or more. Nuwellis Inc. markets its products to hospitals and clinics through a direct salesforce in the United States and independent specialty distributors in select international markets. The company also advances pediatric innovations like the Vivian pediatric system, focusing on safer fluid management in complex clinical scenarios. Founded in 1999 and headquartered in Eden Prairie, Minnesota, Nuwellis Inc. plays a key role in enhancing cardiorenal care by centralizing fluid management in treatment protocols.